Werewolf Therapeutics Director Liquidates 22,184 Shares Amid 24% Sharefall – Investors Warn of Further Price Decline

Insider Selling on a Volatile Stage

On May 18, 2026, EVNIN LUKE sold 22,184 shares of Werewolf Therapeutics’ common stock under a Rule 10b‑5‑1 plan, fetching a weighted average price of $0.50—just a fraction above the closing price of $0.4284. The transaction, while modest in dollar terms, is part of a broader wave of insider activity that has already seen the company’s shares tumble 24 % in a single week and more than 50 % year‑to‑date. For investors, the sale is a signal that senior stakeholders are liquidating positions rather than accumulating, a move that could foreshadow further price erosion if the market interprets the outflow as a lack of confidence in the company’s near‑term prospects.

What This Means for Investors and the Company

Werewolf’s valuation, sitting at roughly $25 million, is already precariously low, with a negative price‑earnings ratio and a steep annual decline in share price. Insider sales, especially by a director who also manages multiple investment funds linked to the company, intensify concerns that management may lack the conviction or financial cushion to weather ongoing developmental setbacks. If the trend continues, the stock could spiral downward, forcing the company to consider alternative financing—perhaps a secondary offering or a debt round—at even lower valuations, which would dilute existing shareholders further. Conversely, if the company delivers a breakthrough in its immuno‑stimulatory pipeline, the insider sales could be viewed as “good‑timed” divestments, potentially reducing the perceived risk premium.

EVNIN LUKE: A Pattern of Opportunistic Selling

Reviewing EVNIN’s filing history reveals a consistent pattern of selling sizable blocks of shares, often in the high‑thousands, at prices that hover near the mid‑$0.50 range during the current trading cycle. Prior to the May 18 sale, he liquidated over 70,000 shares on May 17 and 30,000 shares on May 16, all under the same 10b‑5‑1 plan. Earlier in the year, he executed large sales of 300,000+ shares at $0.70‑$0.80 levels, and even a 100,000‑share sale at $1.14 in December 2025. These transactions suggest a strategy of incremental divestiture rather than a single “dump” event, likely aimed at minimizing market impact while steadily reducing exposure. The repeated use of multiple affiliated funds indicates a desire to spread risk across investment vehicles.

Investor Takeaway

For the discerning investor, the key takeaway is that insider selling, especially at this frequency, may be a warning bell rather than a routine exercise. While the director’s sales are structured under a pre‑arranged plan and therefore not necessarily a reaction to negative news, they do reinforce a narrative of declining confidence in Werewolf’s commercial trajectory. Traders should monitor whether the selling volume continues to outpace new capital inflows, and whether the company delivers any significant clinical or regulatory milestones that could reverse the trend. Until such catalysts materialize, the stock’s path appears to be a steep descent, amplified by insider liquidity outflows and an already weak market foundation.